Akorn (AKRX) Receiving Somewhat Favorable Press Coverage, Study Finds

News coverage about Akorn (NASDAQ:AKRX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akorn earned a news impact score of 0.18 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.0715656594514 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Several analysts have recently commented on the stock. Jefferies Group set a $34.00 target price on shares of Akorn and gave the stock a “hold” rating in a research note on Sunday, October 29th. Zacks Investment Research upgraded shares of Akorn from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Piper Jaffray Companies set a $34.00 target price on shares of Akorn and gave the stock a “hold” rating in a research note on Sunday, October 22nd. Royal Bank Of Canada restated a “hold” rating and issued a $34.00 target price on shares of Akorn in a research note on Tuesday, October 3rd. Finally, BidaskClub downgraded shares of Akorn from a “sell” rating to a “strong sell” rating in a report on Saturday, August 19th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. Akorn currently has a consensus rating of “Hold” and an average price target of $30.71.

Akorn (NASDAQ:AKRX) opened at $32.80 on Wednesday. The company has a current ratio of 4.16, a quick ratio of 3.17 and a debt-to-equity ratio of 0.92. Akorn has a twelve month low of $17.61 and a twelve month high of $34.00. The firm has a market cap of $4,097.31, a PE ratio of 20.35, a price-to-earnings-growth ratio of 2.05 and a beta of 1.33.

In other news, Director Brian Tambi sold 15,100 shares of Akorn stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $33.35, for a total transaction of $503,585.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 28.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Akorn (AKRX) Receiving Somewhat Favorable Press Coverage, Study Finds” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://ledgergazette.com/2017/12/06/akorn-akrx-earning-somewhat-positive-media-coverage-analysis-finds.html.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Insider Buying and Selling by Quarter for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply